Expert Outlook: Inari Medical Through The Eyes Of 9 Analysts
Portfolio Pulse from Benzinga Insights
Inari Medical (NASDAQ:NARI) has been analyzed by 9 analysts over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target is $58.78, down from $60.17. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Inari Medical's revenue growth is notable at 22.53%, but its net margin and ROA are below industry averages, indicating profitability challenges.
September 17, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Inari Medical has received mixed analyst ratings, with a current average price target of $58.78, down from $60.17. The company's revenue growth is strong at 22.53%, but profitability metrics like net margin and ROA are below industry averages.
The mixed analyst ratings and slight decrease in average price target suggest a neutral short-term impact on NARI's stock price. While revenue growth is strong, the company's profitability challenges may offset positive sentiment. The analysis reflects a balanced view of the company's current market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100